News & Updates

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.

Use of vitamin D but not calcium supplementation appears effective at preventing multiple sclerosis (MS) in individuals of European descent, suggests a recent study.

A recent study has shown that antipsychotic monotherapy does not reduce the risk of hospitalization for severe physical health problems when compared with polypharmacy in patients with schizophrenia.

A meta-analysis of randomized trials has revealed that influenza vaccination is effective at preventing all-cause mortality, cardiovascular mortality, major acute cardiovascular events, and acute coronary syndrome (ACS) among patients with coronary artery disease (CAD), particularly in those with ACS.

The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.

Withholding treatment in individuals with glaucoma does not appear to lead to serious consequences in terms of visual function, according to a study.

Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.